{"filings":[{"id":170541,"accession_number":"0001193125-25-057850","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Bala S. Manian resigns from Vaccinex board effective March 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bala S. Manian resigned as a director of Vaccinex, Inc. effective immediately on March 18, 2025.","Departure was not due to any disagreement with the Company on operations, policies, or practices.","No replacement or further board changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170540,"accession_number":"0001193125-25-049988","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Vaccinex voluntarily delists from Nasdaq; Form 25 filing expected March 17, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq trading suspended since December 18, 2024 following a hearing panel determination to delist.","Company notified Nasdaq on March 7, 2025 of its intention to delist; filing Form 25 on or about March 17.","Stock will continue to trade on OTC Pink under symbol VCNX.","Vaccinex plans to continue development of pepinemab in Alzheimer's and cancer via partnerships and grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187535,"accession_number":"0001193125-24-280155","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Vaccinex receives Nasdaq delisting notice; trading suspended Dec 18, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist VCNX for failing to maintain $2.5M minimum stockholders' equity.","Trading suspension effective at open of trading on Wednesday, December 18, 2024.","Company expects common stock to be quoted on OTC Markets Group under symbol VCNX.","Press release issued December 17, 2024 announcing the delisting determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187534,"accession_number":"0001193125-24-258757","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises $2.15M in private placement of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 76,909 shares at $3.25/share and pre-funded warrants for 584,646 shares at $3.2499 each.","Private placement closed Nov 14, 2024; aggregate gross proceeds of approx. $2.15 million.","Investors include FCMI Parent Co. (controlled by Chair Albert Friedberg) and Vaccinex (Rochester) L.L.C. (controlled by CEO Maurice Zauderer).","Pre-funded warrants exercisable immediately at $0.0001/share with a 39.99% beneficial ownership limitation.","Agreement includes participation rights in any subsequent offering and customary resale registration rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187533,"accession_number":"0001193125-24-235251","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaccinex receives Nasdaq delisting notice for failing equity standard; will appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement for continued listing.","Nasdaq granted extension until Sept 30, 2024, to regain compliance; company did not comply.","On Oct 7, 2024, Nasdaq determined to delist unless company timely appeals to a Hearings Panel.","Company intends to appeal, which automatically stays suspension and delisting pending Panel decision.","No assurance that Hearings Panel will grant continued listing or that compliance will be achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204021,"accession_number":"0001193125-24-221790","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$6.2M via warrant exercise & new warrant issuance; insiders participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercised 1,067,492 existing warrants at $5.636/share; gross proceeds ~$6.2M.","Company issued 1,601,238 new warrants at $0.125 each, exercisable at $5.636, expiring 2029.","Insiders (chair and CEO controlled entities) participated; shares/warrants issued in private placement.","Company must file resale registration statement by Oct 17, 2024 for new warrant underlying shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204020,"accession_number":"0001193125-24-218870","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex director Chrystyna Bedrij Stecyk resigns effective September 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chrystyna Bedrij Stecyk resigned as director of Vaccinex, Inc. effective immediately.","Resignation was not due to any disagreement with the Company on operations, policies, or practices.","No replacement director was announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204019,"accession_number":"0001193125-24-203149","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vaccinex calls warrants after positive Alzheimer's trial FDG-PET signal","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Warrants from Oct/Nov 2023, Feb/Mar 2024 financings called for cancellation at $0.0001/share.","Call triggered by statistically significant increase in FDG-PET signal in SIGNAL-AD pepinemab trial.","Warrant holders have 20 or 30 trading days to exercise; unexercised warrants auto-cancel.","Company plans to explore additional financing options, including warrant inducement or exchange.","No guarantee of warrant exercise or success of any potential financing transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204018,"accession_number":"0001193125-24-200272","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.","In MCI patients, reduced astrocyte reactivity (GFAP) and neuronal damage marker p-tau217; no effect in early dementia.","Cognitive decline slowed in MCI per iADRS and ADAS-Cog13; no benefit in early dementia group.","Company plans to pursue a development partnership to reduce operating expenses going forward.","Pepinemab was well-tolerated, consistent with prior Huntington's disease studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204017,"accession_number":"0001193125-24-189569","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.","Secondary endpoint: statistically significant increase in FDG-PET signal in medial temporal cortex (p=0.0297) in MCI patients over 12 months.","Results echo prior Phase 2 Huntington's data, suggesting similar mechanism targeting astrocyte activation.","Company actively pursuing a pharmaceutical partner for late-stage development in Alzheimer's disease.","Pepinemab has been well-tolerated in over 600 patients across AD, HD, and MS trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220716,"accession_number":"0001193125-24-155612","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.","Database lock expected in June; key outcomes including safety, FDG-PET, and plasma GFAP biomarkers to be reported in July.","Pepinemab targets SEMA4D to inhibit astrocyte reactivity and neuroinflammation, a differentiated mechanism vs. anti-amyloid antibodies.","Study funded by $4.75M from ADDF and $0.75M grant from Alzheimer's Association."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220715,"accession_number":"0001193125-24-135285","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex shareholders elect directors, approve say-on-pay and incentive plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Jacob Frieberg, Albert Friedberg, and Maurice Zauderer as directors with >425k votes each.","Advisory say-on-pay passed with 521,607 votes for vs 27,555 against.","Shareholders chose annual frequency for future say-on-pay votes (539,907 for 1 year).","First amendment to 2018 Omnibus Incentive Plan approved 403,835 for, 146,143 against.","Ratified Deloitte & Touche as auditor for FY2024 with 674,404 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220714,"accession_number":"0001193125-24-094701","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaccinex receives Nasdaq notice for failing minimum equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on April 11, 2024: Vaccinex lacks $2.5M minimum stockholders' equity for continued listing.","Company also fails alternative standards: market value of listed securities $35M or net income $500k.","Deadline to submit compliance plan is May 13, 2024; Nasdaq may grant extension if plan accepted.","No immediate delisting, but failure to regain compliance could lead to delisting of VCNX common stock.","Management evaluating options but cannot assure regaining or maintaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220713,"accession_number":"0001193125-24-083568","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$4.5M via multiple equity financings; issues Series A Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds: ~$1.5M from RDO + PIPE (193K shares and warrants at $7.77/unit).","Additional Private Placement: ~$1.25M from 159,683 shares and warrants at $7.77/unit; insiders participated.","ADDF Transaction: $1.75M from Series A Preferred (5% cumulative dividend, convertible) and warrants for 229,057 shares.","Warrants exercisable at $7.64/share, 5-year term; callable after positive SIGNAL-AD Alzheimer's data release.","Lock-up on insiders through May 12, 2024; company restricted from most equity issuances until June 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240336,"accession_number":"0001193125-24-080804","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex closes $1.5M registered direct offering of 193K shares and warrants at $7.77 combined","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 193,000 shares and warrants for 193,000 shares at $7.77 per unit.","Gross proceeds of approximately $1.5 million from the offering.","Offering previously disclosed on March 27, 2024; closings occurred March 28, 2024.","Concurrent private placement of Common Warrants to purchase up to 193,000 shares of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240335,"accession_number":"0001193125-24-078295","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vaccinex raises ~$1.5M via public offering of 193K shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering combines 193,000 common shares with warrants to purchase equivalent shares at $7.77 per unit.","Gross proceeds of approximately $1.5 million; closing expected on March 28, 2024.","Company prohibited from issuing or announcing new equity for 90 days post-close, with exceptions for insider/charity offerings up to $3M total.","Prior at-the-market offering under Sale Agreement terminated effective March 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240334,"accession_number":"0001193125-24-057888","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex CFO Scott Royer to retire March 14; Controller Jill Sanchez named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Scott Royer notified retirement effective March 14, 2024, not due to any disagreement with the company.","Jill Sanchez, age 52, CPA, to serve as Interim CFO, Principal Financial and Accounting Officer from March 14.","Sanchez has been Vaccinex's Controller since January 2019; no family relationships or reportable transactions.","Royer will cease serving as Principal Financial and Principal Accounting Officer upon retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240333,"accession_number":"0001193125-24-040885","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex enters 8 ActivMAb agreements including 3 major pharma companies for complex membrane targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight new antibody discovery agreements integrate ActivMAb platform, with 3 major pharma/biotech companies and 5 strategic antibody-service partners.","ActivMAb 'Antigen Virus' application targets difficult multi-pass membrane proteins such as GPCRs, ion channels, and chemokine receptors.","Technology enables antibody drug conjugate (ADC) development for cancer; platform uses purified viral presentation for efficient selection.","Agreements signed within last 3 months; CEO cites renewed market optimism after two-year biotech downturn as driver of interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240332,"accession_number":"0001193125-24-037078","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Vaccinex implements 1-for-14 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Split effective 5:00 p.m. ET Feb 19, 2024; shares trade split-adjusted from Feb 20.","Ratio 1-for-14, approved by board and stockholders; new CUSIP 918640301.","Complying with $1.00 minimum bid price required by Nasdaq by March 4, 2024.","Fractional shares rounded up; authorized shares unchanged; equity awards adjusted.","Shares continue trading under symbol VCNX; transfer agent is Computershare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240331,"accession_number":"0001193125-24-033801","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex shareholders approve reverse stock split at ratio of 1:4 to 1:14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved by 7,075,432 votes for, 258,830 against, 37,142 abstain.","Board authorized to implement reverse split at any ratio between 1-for-4 and 1-for-14.","Action likely intended to regain compliance with Nasdaq minimum bid price requirement.","Exact ratio and timing to be determined by Board at its discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240329,"accession_number":"0001193125-24-027618","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K/A","filed_at":"2024-02-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vaccinex amends 8-K to correct Form of Common Warrant filed with Feb. 6 offering","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended Form 8-K filed solely to replace incorrect version of Exhibit 4.2 (Form of Common Warrant).","Corrected warrant form supersedes the one filed in error with the Original 8-K dated Feb. 7, 2024.","No other changes made to the Original 8-K; securities purchase agreement and other exhibits unchanged.","Original 8-K reported a securities purchase agreement and related warrants dated Feb. 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240330,"accession_number":"0001193125-24-026615","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$3.7M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 3.84M shares and warrants for 3.84M shares at $0.725 per unit; also 1.27M pre-funded warrants at $0.7249.","Common warrants exercisable at $1.00/share; pre-funded warrants at $0.0001; both immediately exercisable.","Investors include company chair Albert Friedberg (FCMI) and CEO Maurice Zauderer (Vaccinex Rochester).","Gross proceeds ~$3.7M; closing on Feb 8, 2024.","Executive officers and directors subject to 45-day lock-up on sales of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}